 |
|
New genetic test predicts risk of metastasis in patients with deadly eye cancer
November 15, 2006UCLA surgeons first to biopsy tumor tissue from living eye
Imagine being diagnosed with eye cancer - but your doctor can't tell whether you have the aggressive type that will swiftly spread, causing blindness and death in as early as a year.
A new procedure at UCLA's Jules Stein Eye Institute could reveal this valuable information to ocular melanoma patients and their physicians, providing a clear basis for making treatment and lifestyle choices. Researchers have pioneered the first technique to biopsy tissue from the living eye in order to predict which tumors possess high metastatic risk. The Nov. 15 online edition of the journal Ophthalmology reports the findings, which urge a new treatment strategy for physicians and offer huge medical and psychological benefits to patients.
"For the first time, we have demonstrated that it's safe and feasible to perform a biopsy in the living eye to obtain clear results about whether a tumor has metastatic potential or not," explained Dr. Tara Young, assistant professor of ophthalmology at UCLA's Jules Stein Eye Institute and a Jonsson Comprehensive Cancer Center researcher. "Identifying patients at high risk for metastasis is an important first step toward reducing the death rate of this cancer, which kills nearly half of its patients."
Ocular melanoma attacks the pigment cells in the retina. Earlier studies discovered that patients who are missing one copy of chromosome 3 in their tumor tissue are more likely to have highly aggressive cancers. Half of these patients die within five years, due to metastasis to the liver and other organs.
Using this genetic marker as the starting point for their research, UCLA scientists studied a group of patients who had been newly diagnosed with ocular melanoma. Each patient was scheduled for a standard eye surgery to temporarily implant a small disc designed to shrink the tumor with radiation and hopefully save the eye.
For the first time, UCLA surgeons used an ultra-fine needle to collect cells from the cancer before surgery and send the sample to the lab for culture. After growing the tumor cells, a geneticist analyzed them to determine whether they were missing a copy of chromosome 3.
Of the nine patients in the UCLA study who underwent biopsy, four had tumors identified as high-risk for aggressive metastasis, and five were identified as low-risk.
"When physicians know upfront which patient has a poor prognosis, they will monitor the person more closely to detect metastasis earlier and consider more aggressive treatments to increase their chance of survival," Young emphasized. "Knowledge of metastatic risk will also help patients and their physicians decide whether to pursue clinical trials of experimental therapies that target metastasis.
"Patients understand that no good treatment exists after their cancer spreads - everyone wants to know what their metastasis risk is," she added. "If the risk is low, it's a giant relief and emotional burden off their shoulders. If the risk is high, it enables them to plan arrangements for their family and finances, and make the most of their remaining time alive."
Pioneered by UCLA ophthalmic pathologist Dr. Ben Glasgow, the technique of fine-needle aspiration for collecting cancer cells from the living eye has been the standard of care at the Jules Stein Eye Institute since 2004, but adopted by only a handful of other ophthalmic centers in the nation.
"Until now, there's been little we could do but radiate the patient's eye and ask them to return for a follow-up exam in six months," observed Young. "But it's short-sighted to think of ocular melanoma as related only to the eyeball. Cancer can kill you, regardless of where it originates in the body.
"We've known for 10 years that this genetic marker is linked to fast-growing melanoma," she added. "It's time for ophthalmologists to expand their surgical practice to include the biopsy procedure, and use it to obtain life-saving information for their patients. Only then will we be able to develop strategic approaches to treating the cancer's effect on the whole body."
Although rare, ocular melanoma is the most common eye cancer to strike adults. The National Eye Institute reports some 2,000 newly diagnosed cases of the cancer - roughly seven in 1 million people - per year in the United States and Canada. The disease spans the age and ethnic spectrum, and is not hereditary.
University of California - Los Angeles
"For the first time, we have demonstrated that it's safe and feasible to perform a biopsy in the living eye to obtain clear results about whether a tumor has metastatic potential or not," explained Dr. Tara Young, assistant professor of ophthalmology at UCLA's Jules Stein Eye Institute and a Jonsson Comprehensive Cancer Center researcher. "Identifying patients at high risk for metastasis is an important first step toward reducing the death rate of this cancer, which kills nearly half of its patients."
Ocular melanoma attacks the pigment cells in the retina. Earlier studies discovered that patients who are missing one copy of chromosome 3 in their tumor tissue are more likely to have highly aggressive cancers. Half of these patients die within five years, due to metastasis to the liver and other organs.
Using this genetic marker as the starting point for their research, UCLA scientists studied a group of patients who had been newly diagnosed with ocular melanoma. Each patient was scheduled for a standard eye surgery to temporarily implant a small disc designed to shrink the tumor with radiation and hopefully save the eye.
For the first time, UCLA surgeons used an ultra-fine needle to collect cells from the cancer before surgery and send the sample to the lab for culture. After growing the tumor cells, a geneticist analyzed them to determine whether they were missing a copy of chromosome 3.
Of the nine patients in the UCLA study who underwent biopsy, four had tumors identified as high-risk for aggressive metastasis, and five were identified as low-risk.
"When physicians know upfront which patient has a poor prognosis, they will monitor the person more closely to detect metastasis earlier and consider more aggressive treatments to increase their chance of survival," Young emphasized. "Knowledge of metastatic risk will also help patients and their physicians decide whether to pursue clinical trials of experimental therapies that target metastasis.
"Patients understand that no good treatment exists after their cancer spreads - everyone wants to know what their metastasis risk is," she added. "If the risk is low, it's a giant relief and emotional burden off their shoulders. If the risk is high, it enables them to plan arrangements for their family and finances, and make the most of their remaining time alive."
Pioneered by UCLA ophthalmic pathologist Dr. Ben Glasgow, the technique of fine-needle aspiration for collecting cancer cells from the living eye has been the standard of care at the Jules Stein Eye Institute since 2004, but adopted by only a handful of other ophthalmic centers in the nation.
"Until now, there's been little we could do but radiate the patient's eye and ask them to return for a follow-up exam in six months," observed Young. "But it's short-sighted to think of ocular melanoma as related only to the eyeball. Cancer can kill you, regardless of where it originates in the body.
"We've known for 10 years that this genetic marker is linked to fast-growing melanoma," she added. "It's time for ophthalmologists to expand their surgical practice to include the biopsy procedure, and use it to obtain life-saving information for their patients. Only then will we be able to develop strategic approaches to treating the cancer's effect on the whole body."
Although rare, ocular melanoma is the most common eye cancer to strike adults. The National Eye Institute reports some 2,000 newly diagnosed cases of the cancer - roughly seven in 1 million people - per year in the United States and Canada. The disease spans the age and ethnic spectrum, and is not hereditary.
University of California - Los Angeles
Eye Cancer Current Events and Eye Cancer News RSSBioluminescence imaging used for eye cancer detection
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
UBC researchers discover gene mutation that causes eye cancer
A University of British Columbia geneticist has discovered a gene mutation that can cause the most common eye cancer - uveal melanoma.
St. Jude defines eye cancer gene's role in retinal development
A genetic discovery led by scientists at St. Jude Children's Research Hospital helps answer a long-standing mystery about the eyes of vertebrates, and may translate into a deeper understanding of how genes coordinate the complex process of eye formation and how a rare pediatric eye cancer progresses.
St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory
Investigators at St. Jude Children's Research Hospital have identified the cell that gives rise to the eye cancer retinoblastoma, disproving a long-standing principle of nerve growth and development.
Immune deficiency linked to a type of eye cancer
The incidence of squamous cell eye cancer is greater among kidney transplant patients and people with human immunodeficiency virus (HIV) than the general public, which suggests the disease is associated with immune deficiency.
St. Jude announces breakthrough in eye cancer treatment
Scientists at St. Jude Children's Research Hospital have demonstrated in a mouse model a new, locally applied treatment for the eye cancer retinoblastoma that not only greatly reduces the size of the tumor, but does so without causing the side effects common with standard chemotherapy.
Genetic insights may explain retinal growth, eye cancer
Investigators at St. Jude Children's Research Hospital have discovered the role of several key genes in the development of the retina, and in the process have taken a significant step toward understanding how to prevent or cure the potentially deadly eye cancer retinoblastoma.
Radiation therapy can help spare vision in patients with melanoma of the eye
Treating a rare form of eye cancer with radiation therapy can spare patients from significant vision loss.
Retinoblastoma researchers find success with two-drug combination
Retinoblastoma is a tumor that arises in the cells of the retina, the light-sensitive tissue at the back of the eyeball, following mutation of the gene RB1.
More Eye Cancer Current Events and Eye Cancer News Articles
 |
The Will to Live: The Perks of Cancer Through the Eyes of a Survivor by Erin Ley (Author) Erin Ley was diagnosed with cancer (non-Hodgkins lymphoblastic lymphoma) when she was twenty-five, and then went through over two years of aggressive chemotherapy and radiation treatments. The Will to Live is the story of her struggle to take something positive out of this harrowing experience. In this deeply personal account of her physical, mental and spiritual journey, Erin shares what she learned about how to find and appreciate the marvelous wonders that can arise from a period of extreme pain, fear and helplessness. Now that she is living her “new and improved” life, Erin hopes that cancer patients and their families will draw comfort, optimism and inspiration from reading about her struggle and success. Ten percent of the proceeds of The Will to Live will be donated to the... |
 |
Prepackaged (7 3/4 in.) Cancer Awareness Bracelet 18 Colors, 8mm by Allred Beads Product Description Made with 8mm cats eye beads (the red bead here is a glass pearl, not a cat's eye bead), silver plated 5mm round beads,silver plated Bali Daisy Spacer beads and a cancer awareness ribbon. Finished with a strong lobster clasp with strong professional wire. These bracelets are 7 3/4 inches long, this will fit most adults and is a good universal size. They also come with two extension rings per bracelet just in case. The bracelets come mounted on a card, prepackaged with the meaning of all the cancer colors printed on the back of the card. A great way to get bracelets for any cancer awareness event, to resell for a good cause or just to wear your self to show support for cancer awareness. Colors used in this bracelet and their meanings: You will receive the... |
 |
Fight Against Eye Cancer Long Sleeve T-shirt Large White by Shop Zeus |
 |
Cancer - Coconut - Sun's Eye Zodiac Oils - 1/2 Ounce Bottle by Sun's Eye Oils |
 |
Stila Eye Shadow Pan, Kitten .09 oz (2.6 g) by Stila Corp Kitten (shimmering nude pink) Inspire your inner artist and create a palette of color with stila's award-winning eye shadows. Our assortment offers something for every stila girl - from classic neutrals to the hippest, trend-setting shades in mattes and shimmers! Our award-winning shades are known for their high-quality formula and texture. They're sold in pans so you can create your own custom kit! Made in USA |
 |
Cancer of the Mind's Eye Fall to Prey (Primary Contributor) |
 |
Olympian Labs Lutein Capsules, 20mg, 60-Count Bottle by Olympian Labs Lutein belongs to the xanthophylls, a subgroup of the carotene family. Carotenoids are a group of over 600 compounds known as the carotenoid pigments. These pigments give yellow, green or orange coloration to vegetables and fruits and are precursors for vitamin A or retinol, an essential chromophore in all known visual systems. Lutein is naturally found in egg yolk and several plants including collard greens, kale, leeks, peas, romaine lettuce and spinach. Lutein is a yellow carotenoid pigment produced by plants and found in our eyes in the central area of the retina, called macula. The macula is a small, concentrated collection of photosensitive cells in the middle of the retina, directly behind the lens, that is responsible for central vision. In front of the photoreceptor is the neural... |
 |
Michael & Anne Marie Gerosimo Also With: David Collins (Producer), Michael Williams (Producer), David Metzler (Producer), Frances Berwick (Producer), Amy Introcaso-Davis (Producer), Christian Barcellos (Producer) |
 |
Scar Healing Silicone Disc 1.6" Diameter (3 Disc Per Package) for Smaller Round Scars Caused By Acne, Minor Cuts, Abrasions, Mole and Wart Removal, Skin Cancer Removal, Liposuction, Arthroscopic Surgery, Body Piercings (Ears, Nose) and Plastic Surgery Procedures to the Eyes, Chin or Ears. ***Note: You Can Also Cut the Silicone Sheeting to Size Leaving ¼ Inch Overlap. by ReJuveness LLC ReJuveness silicone sheeting is a FDA Class-1 medical device clinically proven and guaranteed to provide results with our non-invasive scar treatment. Topically applied ReJuveness silicone sheeting has been shown to be effective for scar therapy in over 50 studies, regardless of the scar type, location, and age. An international panel of scientists and experts on scarring, reviewing all the studies and literature on available scar treatments, determined silicone sheeting to be a leading non-surgical evidence-based scar treatment for scar management and scar prevention. Works Better Than Adhesive Silicone Sheets That Require Tape After a Few Days of usage, Adhesive Clogs Pours in Silicone Sheeting Reducing Effectiveness and Is More Costly Over the Treatment Period. Testimonials:"I just... |
 |
Pink Ribbon Cats Eye & Pearl Bracelet by Arkansas Flag and Banner 2.5 in. diameter This stretch bracelet has faux pink pearl & silver beads with pink ribbon charms. Lots of fun to wear and a novel way to attract attention to fighting breast cancer!
|
| © 2009 BrightSurf.com |